Register
Login:
Share:
Email Facebook Twitter




Immupharma Share Price (IMM)



Share Price Information for Immupharma (IMM)


Share Price: 33.50Bid: 32.00Ask: 35.00Change: 0.00 (0.00%)No Movement on Immupharma
Spread: 3.00Spread as %: 9.38%Open: 34.00High: 34.00Low: 33.50Yesterday’s Close: 33.50

Immupharma Plc Ord 10P

Immupharma is listed in the FTSE AIM All-Share
Immupharma is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
33.50

Share Price SpacerBid
32.00

Share Price SpacerAsk
35.00

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
37,701

Share Price SpacerOpen
34.00

Share Price SpacerHigh
34.00

Share Price SpacerLow
33.50

Share Price SpacerClose
33.50

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 121.78m £40.80m 10,000

52 Week High 48.25 52 Week High Date 2-JUN-2016
52 Week Low 19.75 52 Week Low Date 2-DEC-2015

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
8 18,468 19,233 -7.614 -4.40 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

29-Jun-16
14:02:06
34.25
1,424
Buy* 
33.00
35.00
487.72
Trade Type:
Ordinary

29-Jun-16
13:37:06
33.50
6,606
Sell* 
33.00
35.00
2,213
Trade Type:
Ordinary

29-Jun-16
13:14:54
34.25
1,715
Buy* 
33.00
35.00
587.39
Trade Type:
Ordinary




View more Immupharma trades >>

Directors Deals for Immupharma (IMM)
Trade DateActionNotifierPriceCurrencyAmountHolding
30-Apr-15Notification of Holding
Trade Notifier Information for Immupharma
Stephane Robert George Mery held the position of Non-Executive Director at Immupharma at the time of this trade.
 Stephane Robert George Mery
002259
24-Jan-13Sell
Trade Notifier Information for Immupharma
Ajay Agrawal held the position of Non-Executive Director at Immupharma at the time of this trade.
 Ajay Agrawal
57GBX62,1690
24-Jan-12Buy
Trade Notifier Information for Immupharma
Ajay Agrawal held the position of Non-Executive Director at Immupharma at the time of this trade.
 Ajay Agrawal
80GBX62,1690
View more Immupharma directors dealings >>



Date/TimeAuthorSubjectShare PriceOpinion
Wed 23:22OlderandwiserRE: boom33.50No Opinion
Leas/boom, helpful posts, all.

I am amazed that Benlysta got P3 approval given headline numbers like those. There must be more to their case than that surely. Or was the plight of Lupus sufferers so grim that ANY statistical improvement at that time would be welcomed with open arms?

On another point, the presentation talks of n = 200/study for Imm's P3 trial. But if one group is taking the active drug and the other is taking the placebo, isn't that 2 * 200 = 400 patients enrolled?
Wed 22:57leasboom33.50No Opinion
thanks, promising reading. o/t hope you and all your family are keeping well. Although post less frequently now I often check out your contributions. All without exception are informative and balanced. In any case atb and bonsoir mon ami
Wed 22:28boomorbustleas/older33.50No Opinion
The slide on page 12 of this presentation has a nice summary of the headline results for both Benlysta and Lupuzor for a quick comparison.

http://www.proactiveinvestors.co.uk/upload/SponsorFile/File/2016_02/ImmuPharma-Presentation-Feb-2016-proactive-investor.pdf
Wed 22:01leasRE: hunkymunky33.50No Opinion
O&W rambling on a bit now and will take to the fields for a few more weeks but I did read that benlysta will be in the top 10 drugs for driving growth in the company between 2015 and 2020. It was expected to rise further after that date with increased revenue. Their calculations are not based on any other product being successful in that market.
Wed 21:52leasRE: hunkymunky33.50No Opinion
Wed 21:49leasRE: hunkymunky33.50No Opinion
Olderandiser, during P2 trials over 100 patients completed the 12 week course and over half completed a further 12 weeks. There were no reported adverse affects from the dosage and a decrease in the SLEDAI score. 12 being severe and 3 being mild. I think from memory the average reduction was five. That itself is significant and probably life changing from those suffering from lupus. Not sure why only half of them completed a further 12 weeks but would guess their fitness and condition had a… Read More

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Immupharma (IMM) >>

Please login or register to post a message on Share Chat.






Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.